Check-Cap (Check-Cap) Common Stock : $83.74 Mil (As of Sep. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Check-Cap Common Stock?

Check-Cap's quarterly common stock increased from Mar. 2023 ($83.71 Mil) to Jun. 2023 ($83.73 Mil) and increased from Jun. 2023 ($83.73 Mil) to Sep. 2023 ($83.74 Mil).

Check-Cap's annual common stock increased from Dec. 2020 ($31.65 Mil) to Dec. 2021 ($68.79 Mil) and increased from Dec. 2021 ($68.79 Mil) to Dec. 2022 ($83.66 Mil).

Check-Cap Common Stock Historical Data

The historical data trend for Check-Cap's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Check-Cap Common Stock Chart

Check-Cap Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Common Stock

Get a 7-Day Free Trial

3.46

5.41

31.65

68.79

83.66

Check-Cap Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Common Stock	Get a 7-Day Free Trial															83.65	83.66	83.71	83.73	83.74

Check-Cap Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Check-Cap (Check-Cap) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Check-Cap Ltd (NAS:CHEK) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

7CC:Germany

Address

29 Abba Hushi Avenue, Check-Cap Building, P.O. Box 1271, Isfiya, ISR, 3009000

Website

https://www.check-cap.com

Check-Cap Ltd is a clinical-stage medical diagnostics company engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The company is developing C-Scan, the first capsule-based system for preparation-free, colorectal cancer screening. Its scanning capsule will be swallowed and propelled by natural motility through the gastrointestinal tract and excreted naturally with no need for retrieval for data collection. The operations of the company are presently located in Israel, but it currently expects to market products in the United States, Europe, Israel and Japan.